Cargando…

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.

The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rathnasinghe, Raveen, Salvatore, Mirella, Zheng, Hongyong, Jangra, Sonia, Kehrer, Thomas, Mena, Ignacio, Schotsaert, Michael, Muster, Thomas, Palese, Peter, García-Sastre, Adolfo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366806/ https://www.ncbi.nlm.nih.gov/pubmed/34401874 http://dx.doi.org/10.21203/rs.3.rs-668116/v1

Ejemplares similares

Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

The virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Replication-Competent ΔNS1 Influenza A Viruses Expressing Reporter Genes
por: Nogales, Aitor, et al.
Publicado: (2021)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine
por: Jangra, Sonia, et al.
Publicado: (2022)

A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2020)

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
por: Amanat, Fatima, et al.
Publicado: (2021)

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
por: Sun, Weina, et al.
Publicado: (2021)

Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultraviolet C (UVC) irradiation device
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia
por: Chang, Lauren A., et al.
Publicado: (2023)

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

Novel vaccine strategies against emerging viruses
por: García-Sastre, Adolfo, et al.
Publicado: (2013)

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera
por: Rathnasinghe, Raveen, et al.
Publicado: (2022)

A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
por: Jangra, Sonia, et al.
Publicado: (2021)

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
por: White, Kris M., et al.
Publicado: (2021)

TIV Vaccination Modulates Host Responses to Influenza Virus Infection that Correlate with Protection against Bacterial Superinfection
por: Choi, Angela, et al.
Publicado: (2019)

Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection
por: Kaul, Drishti, et al.
Publicado: (2020)

Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model
por: Liu, Wen-Chun, et al.
Publicado: (2019)

Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses
por: Choi, Angela, et al.
Publicado: (2020)

Author Correction: Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection
por: Kaul, Drishti, et al.
Publicado: (2020)

Zika Virus Alters DNA Methylation of Neural Genes in an Organoid Model of the Developing Human Brain
por: Janssens, Sylvie, et al.
Publicado: (2018)

Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
por: Escalera, Alba, et al.
Publicado: (2022)

Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model
por: Liu, Wen-Chun, et al.
Publicado: (2021)

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine
por: Jangra, Sonia, et al.
Publicado: (2020)

Influenza Vaccines: A Moving Interdisciplinary Field
por: Schotsaert, Michael, et al.
Publicado: (2014)

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling
por: Miorin, Lisa, et al.
Publicado: (2020)

Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1
por: Zamarin, Dmitriy, et al.
Publicado: (2005)

Transmission of Influenza Virus via Aerosols and Fomites in the Guinea Pig Model
por: Mubareka, Samira, et al.
Publicado: (2009)

Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain
por: Steel, John, et al.
Publicado: (2010)

Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice
por: Liu, Yonghong, et al.
Publicado: (2021)

Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian Hamsters
por: García-Bernalt Diego, Juan, et al.
Publicado: (2023)

An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus
por: Juozapaitis, Mindaugas, et al.
Publicado: (2014)

Host immune response–inspired development of the influenza vaccine
por: Choi, Angela, et al.
Publicado: (2020)

Contribution of the Purinergic Receptor P2X7 to Development of Lung Immunopathology during Influenza Virus Infection
por: Leyva-Grado, Victor H., et al.
Publicado: (2017)

Generation of an Attenuated Chimeric Bat Influenza A Virus Live-Vaccine Prototype
por: Ran, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mhnctu70bi9jeghhr04nn75uin